Reliability, Validity, and Cross-cultural Adaptation of the Turkish Version of the Victorian Institute of Sports Assessment for Gluteal Tendinopathy (VISA-G) Questionnaire

April 6, 2025 updated by: Halime ARIKAN, Gazi University
The purpose of this study was to investigate adaptation, validity, and reliability of the Turkish version of the Victorian Institute of Sports Assessment for Gluteal Tendinopathy (VISA-G) Questionnaire.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Gluteal tendinopathy, also known as greater trochanteric pain syndrome, interferes with physical function and sleep, and is characterized by pain and tenderness over the greater trochanter.Clinical risk factors for the development of this condition include advanced age, female gender, back pain, overweight / obesity, poor abductor hip function, altered gait parameters, and psychological distress. The Victorian Institute of Sports Assessment for Gluteal tendinopathy (VISA-G) Questionnaire has recently designed as a patient-reported condition-specific outcome measurement tool to assess disability due to tendinopathy. VISA-G is scored between 0 and 100 (a higher score is expected) and consists of eight items covering three main areas (pain, function, and current activity level). Visual analog score for pain (0-10), the effect of pain on weight-bearing activities (0-30), and difficulty and / or function-related stairs use, including lying on the symptomatic side (0-10), climbing ramps (0-10), standing up without sitting (0-10), home or garden work (0-10) and regular exercise (0-10), physical activity and sports participation (0-10) are evaluated. The study is planned with 40 individuals with gluteal tendinopathy. After questioning the sociodemographic characteristics of the individuals, the patients will be asked to fill in VISA-G, Short Form-36, International Physical Activity Questionnaire, Numeric Rating Scale, Oswestry Disability Index, Oxford Hip Score and modified Harris Hip Score.Test-retest will be re-applied to those of the same individuals who can be reached after 1 week. The results will be analyzed using the SPSS version 22.0 computer package program.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
108

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
    • None Selected
      • Ankara, None Selected, Turkey, 06490
        • Halime ARIKAN

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

The study population will consist of individuals with diagnosis of greater trochanteric pain syndrome and gluteal tendinopathy.

Description

Inclusion Criteria:

  • Trochanteric bursitis and/or gluteal tendinopathy,
  • Lateral hip pain,
  • Pain on palpation of the greater trochanter,
  • History of pain when lying on the ipsilateral side or during weight-bearing activities, aggravated by activity for more than 3 months.

Exclusion Criteria:

  • Hip osteoarthritis,
  • Systemic inflammatory disease such as rheumatoid arthritis,
  • Lumbar spine nerve root findings,
  • History of lumbar spine or ipsilateral hip joint surgery,
  • Osteogenic disease such as Paget's disease,
  • Corticosteroid injection to the ipsilateral hip in the past 3 months,
  • Hip surgery.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Patients group
Individuals with greater trochanteric pain syndrome and gluteal tendinopathy
Other: Survey study
Victorian Institute of Sports Assessment for Gluteal Tendinopathy (VISA-G) Questionnaire will be applied.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Victorian Institute of Sports Assessment for Gluteal Tendinopathy (VISA-G) Questionnaire
Time Frame: 10 minutes
Victorian Institute of Sports Assessment for Gluteal Tendinopathy Questionnaire is designed to assess disability due to gluteal tendinopathy.
10 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Gazi University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Seyit CITAKER, Dr., Gazi University, Faculty of Health Sciences
  • Principal Investigator: M. Baybars ATAOGLU, Dr., Gazi University, Faculty of Medicine
  • Principal Investigator: Gokhan MARAS, MSc., Gazi University, Faculty of Health Sciences
  • Principal Investigator: Halime ARIKAN, MSc., Ankara University, Faculty of Health Sciences
  • Principal Investigator: I. Hazal AYAS, MSc., Gazi University, Faculty of Health Sciences
  • Principal Investigator: Beyza YAZGAN DAGLI, MSc., Gazi University, Faculty of Health Sciences

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
January 1, 2022

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
June 1, 2022

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
July 1, 2022

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
January 10, 2021

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 10, 2021

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
January 13, 2021

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
April 8, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 6, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
January 1, 2022

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • E.137836

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Sharing Supporting Information Type

  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings